Advanced

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.

Vesikari, Timo; Brodszki, Nicholas LU ; van Damme, Pierre; Diez-Domingo, Javier; Icardi, Giancarlo; Kjeld Petersen, Lone; Tran, Clément; Thomas, Stéphane; Luxembourg, Alain and Baudin, Martine (2015) In Pediatric Infectious Disease Journal 34(9). p.992-998
Abstract
A 9-valent human papillomavirus (9vHPV) vaccine has been developedto prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV [qHPV] vaccine), as well as 5additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine vs. the qHPV vaccine in 9-15-year-old girls.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Pediatric Infectious Disease Journal
volume
34
issue
9
pages
992 - 998
publisher
Lippincott Williams & Wilkins
external identifiers
  • pmid:26090572
  • wos:000360398600016
  • scopus:84940027111
ISSN
1532-0987
DOI
10.1097/INF.0000000000000773
language
English
LU publication?
yes
id
4385140e-f7eb-40d8-841b-4e8bc14cdafb (old id 7484626)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26090572?dopt=Abstract
date added to LUP
2015-07-08 20:01:06
date last changed
2017-10-29 03:12:18
@article{4385140e-f7eb-40d8-841b-4e8bc14cdafb,
  abstract     = {A 9-valent human papillomavirus (9vHPV) vaccine has been developedto prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV [qHPV] vaccine), as well as 5additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine vs. the qHPV vaccine in 9-15-year-old girls.},
  author       = {Vesikari, Timo and Brodszki, Nicholas and van Damme, Pierre and Diez-Domingo, Javier and Icardi, Giancarlo and Kjeld Petersen, Lone and Tran, Clément and Thomas, Stéphane and Luxembourg, Alain and Baudin, Martine},
  issn         = {1532-0987},
  language     = {eng},
  number       = {9},
  pages        = {992--998},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {Pediatric Infectious Disease Journal},
  title        = {A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.},
  url          = {http://dx.doi.org/10.1097/INF.0000000000000773},
  volume       = {34},
  year         = {2015},
}